Tonix Pharmaceuticals Holding is a clinical-stage biopharmaceutical company focused on discovering, acquiring and developing drugs and biologics to treat and prevent human disease. Co.'s portfolio includes biologics to prevent infectious diseases and small molecules and biologics to treat pain, psychiatric and addiction conditions. Co.'s key product candidate, TNX-102 SL, is a proprietary sublingual tablet formulation of cyclobenzaprine, designed for bedtime administration. Co. also has a pipeline of other drug and biologic candidates, including, TNX-601 CR, a pre-Investigational New Drug application daytime treatment for depression and Neurocognitive Dysfunction from Corticosteroids. The TNXP stock yearly return is shown above.
The yearly return on the TNXP stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TNXP annual return calculation with any dividends reinvested as applicable (on ex-dates).
|